SHANGHAI--(BUSINESS WIRE)--EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the appointment of Dr. Xinyi “David” Gu ...
Mr. David Gu is Partner at Capula Investment Management LLP. Previously, Mr. Gu spent 20 years at Bank of America Merrill Lynch where he was most recently the Global Head of Rates and Currencies and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results